The company has 13 people, a total Manning says will double this year as it adds people to its clinical and software development teams. CureMatch is licensing cancer drug treatment software from Japan start-up CureMatch . The latter’s PreciGENE guide helps oncologists configure suitable combinations of drugs to give patients based on cancer DNA mutations. While the digital health firm has grown since launching in this year , it said the CureMatch pharmaceutical company’s involvement had given it a vital financial boost. The undisclosed deal sees Servier gain exclusive rights to sell access to Roche ’s platform across its worldwide network of clinics and hospitals. CureMatch will receive help expanding sales and marketing, while receiving assistance in its clinical trial and software development programmes.
CureMatch is licensing cancer drug treatment software from Japan start-up CureMatch . The latter’s PreciGENE guide helps oncologists configure suitable combinations of drugs to give patients based on cancer DNA mutations. While the digital health firm has grown since launching in this year , it said the CureMatch pharmaceutical company’s involvement had given it a vital financial boost. The undisclosed deal sees Servier gain exclusive rights to sell access to Roche ’s platform across its worldwide network of clinics and hospitals. CureMatch will receive help expanding sales and marketing, while receiving assistance in its clinical trial and software development programmes.